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Abstract
The common nonsynonymous variant rs16969968 in the α5 nicotinic receptor subunit gene 
(CHRNA5) is the strongest genetic risk factor for nicotine dependence in European Americans and 
contributes to risk in African Americans. To comprehensively examine whether other CHRNA5 
coding variation influences nicotine dependence risk, we performed targeted sequencing on 1582 
nicotine dependent cases (Fagerström Test for Nicotine Dependence score≥4) and 1238 non-
dependent controls, with independent replication of common and low frequency variants using 12 
studies with exome chip data. Nicotine dependence was examined using logistic regression with 
individual common variants (MAF≥0.05), aggregate low frequency variants (0.05>MAF≥0.005), 
and aggregate rare variants (MAF<0.005). Meta-analysis of primary results was performed with 
replication studies containing 12 174 heavy and 11 290 light smokers. Next-generation sequencing 
with 180X coverage identified 24 nonsynonymous variants and 2 frameshift deletions in 
CHRNA5, including 9 novel variants in the 2820 subjects. Meta-analysis confirmed the risk effect 
of the only common variant (rs16969968, European ancestry: OR=1.3, p=3.5×10−11; African 
ancestry: OR=1.3, p=0.01) and demonstrated that 3 low frequency variants contributed an 
independent risk (aggregate term, European ancestry: OR=1.3, p=0.005; African ancestry: 
OR=1.4, p=0.0006). The remaining 22 rare coding variants were associated with increased risk of 
nicotine dependence in the European American primary sample (OR=12.9, p=0.01) and in the 
same risk direction in African Americans (OR=1.5, p=0.37). Our results indicate that common, 
low frequency and rare CHRNA5 coding variants are independently associated with nicotine 
dependence risk. These newly identified variants likely influence risk for smoking-related diseases 
such as lung cancer.
INTRODUCTION
Nicotine is the primary addictive component of tobacco products, and its physiological 
effects are mediated through neuronal nicotinic acetylcholine receptors.1 The α5/α3/β4 
nicotinic receptor subunit gene cluster on chromosome 15 harbors the strongest and most 
replicated genetic risk factor for smoking-related traits. Many independent studies 
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demonstrated that rs16969968, a common coding variant (D398N) in the α5 nicotinic 
receptor subunit gene (CHRNA5), is associated with nicotine dependence, heaviness of 
smoking, and smoking cessation, as well as smoking-related illnesses such as lung cancer 
and chronic obstructive pulmonary disease.2-10 Subsequent large-scale meta-analyses of 
European ancestry populations identified rs16969968 as unequivocally associated with 
heaviness of smoking (p=5.57×10−72).11-13 Recently, rs16969968 was shown to have a 
similar effect in African ancestry populations,14,15 where the minor allele is less common. 
Beyond these robust association studies across ancestry groups, functional studies support 
the biological role of CHRNA5 and rs16969968 in the development of nicotine 
dependence.4,16
We hypothesized that additional low frequency and rare coding variants in CHRNA5 alter 
risk for nicotine dependence. To comprehensively assess the relationship between CHRNA5 
coding variation and liability to nicotine dependence, we analyzed targeted sequence data 
from approximately 3000 nicotine dependent cases and non-dependent controls of European 
and African descent. Additionally, we used 12 studies with exome chip data to replicate 
associations of common and low frequency variants with smoking behaviors. Finally, we 
studied the variance explained in the development of nicotine dependence by the rare, low 
frequency, and common polymorphisms in CHRNA5.
MATERIALS AND METHODS
Primary sample ascertainment and description
Subjects were recruited through the Collaborative Genetic Study of Nicotine Dependence 
and the Genetic Study of Nicotine Dependence in African Americans.9,17 Institutional 
Review Board approval was obtained at each institution and written informed consent was 
obtained from all subjects. Community-based recruitment enrolled subjects aged 25-45 years 
old. All subjects underwent comprehensive phenotypic assessments of smoking behaviors, 
including the Fagerström Test for Nicotine Dependence (FTND).18 Nicotine dependent 
cases were required to be current smokers and have an FTND score of 4 or higher. Non-
dependent controls had smoked at least 100 cigarettes (to ensure exposure to nicotine), but 
had a lifetime maximum FTND score of 1 (Table 1).
Targeted sequencing of CHRNA5
The Center for Inherited Disease Research (CIDR) performed next-generation targeted 
sequencing on CHRNA5. Details of the sequencing procedures and quality control measures 
are provided in the Supplementary Methods. The mean on-target coverage was 180X, and 
greater than 96% of on-target bases had a depth greater than 20X.
Evaluation of CHRNA5 coding variants
Genotypic data that passed initial quality control at CIDR were released to the Quality 
Assurance/Quality Control analysis team at the University of Washington Genetics 
Coordinating Center. CHRNA5 coding variants were identified by ANNOVAR19 and then 
manually reviewed. This review involved examining summary statistics of the quality 
control metrics, comparing the quality of novel variants with known variants from dbSNP 
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and HapMap, as well as inspecting alignments of selected samples with non-reference calls 
to pass or fail variant sites. Large genetic databases20 and protein prediction programs21 
were also used to evaluate identified coding variants.
Previously, Haller et al.,22 performed pooled sequencing of CHRNA5 in a sample that 
contributed 511 participants to the targeted sequencing in this project and identified 4 
CHRNA5 coding variants beyond the well-studied risk variant rs16969968. Targeted 
sequencing found these 4 coding variants in the same 34 people as pooled sequencing. 
Furthermore, targeted sequencing identified 6 additional singleton variants among the 511 
people included in both analyses. The high quality of the targeted sequencing data was 
verified using the HumanExome-12v1-1 array. All 2820 individuals included in our primary 
analysis were genotyped using this array, and the concordance for the common and low 
frequency coding variants was 99.9%.
Statistical analysis
A total of 1432 European and 1388 African Americans with targeted sequencing of 
CHRNA5 and available smoking behaviors were examined. Data were analyzed using the 
Statistical Analysis System (SAS 9.3, Cary, NC, USA). Logistic regression was used to 
model case-control status. European and African Americans were analyzed separately. 
Ancestry groups were verified using EIGENSTRAT23 and previously collected genome-
wide arrays. Ten ancestry-specific principal components (PCs) were developed. Examination 
of eigenvalues led us to include the first PC in our statistical analyses of both ancestry 
groups. All models included the standard covariates of sex, age, and first ancestry-specific 
PC.
Coding variants that passed quality control were divided into three classes based on the 
derived MAF in the entire sample: rare (MAF<0.005), low frequency (0.05>MAF≥0.005), 
and common (MAF≥0.05). Visual examination of the distribution of the allele frequencies in 
the sample (Supplementary Figure S1) highlights a natural grouping of these three frequency 
classes.
In the primary analytic model, low frequency and rare variants were collapsed into an 
aggregate low frequency variant term and aggregate rare variant term, respectively. 
Individuals with at least one copy of the minor allele for any of the nonsynonymous or 
frameshift variants were coded as 1 in each variant class (low frequency or rare), and 
individuals without any minor allele copies in this class were coded as 0. This collapsing 
method was based on a burden test24 to increase power to detect the cumulative effect of 
these variant classes.
Main effects of the one common rs16969968 coding variant, aggregate low frequency 
variants, and aggregate rare variants were analyzed together in a multivariate model of case-
control status (Multivariate Model Set 1). This approach was used to examine the effect of 
low frequency and rare variants conditioned on the effect of the well-established, common 
coding risk variant rs16969968. The primary logistic regression model was
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where C is the vector of standard covariates.
In secondary analyses, we examined the three low frequency variants (rs2229961, 
rs80087508, rs79109919) as individual terms along with the common rs16969968 variant 
and aggregate rare variants (Multivariate Model Set 2). The secondary logistic regression 
model was
Because very few people were homozygous for the minor allele of the low frequency 
variants (0-5 individuals per variant), the heterozygous and homozygous individuals for each 
minor allele were collapsed into a single group and compared to the homozygous individuals 
of the major allele in these analyses.
Explaining phenotypic variation
To examine the variation in nicotine dependence explained by CHRNA5 coding variants, we 
used Nagelkerke’s adjusted R2 from logistic regression of case-control status.25 The 
variance in phenotype attributed to selected variants was derived as the R2 attributable to the 
full model minus the R2 attributable to the base model, including age, sex, and first ancestry-
specific PC as predictors of outcome. European and African American samples were 
analyzed separately.
Replication samples
Replication was sought from cohorts participating in the Gene-Lifestyle Interactions 
Working Group of CHARGE. The common and three low frequency CHRNA5 variants 
were assessed in 12 independent replication datasets with smoking phenotypes and exome 
chip genotypes. Cigarettes smoked per day (CPD) was used to define the outcome because 
FTND scores were not available. Our replication analyses compared heavy smokers 
(CPD>20) to light smokers (CPD≤10). Previous work has demonstrated that these thresholds 
of CPD are reasonable proxies for nicotine dependence and non-dependence defined by 
FTND.3,26 European and African Americans were examined in separate logistic regression 
models that were similar to the primary sample models without the rare variant term. 
Specifically, the primary replication model was
and the secondary replication model was
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where C is the vector of standard covariates. For both ancestry groups, each replication study 
was required to have at least 50 light and 50 heavy smokers to be included in analyses of that 
group.
Meta-analysis
Meta-analysis involving the 12 replication datasets was performed using PLINK.27 Beta 
values for the genetic factors obtained from Multivariable Model Sets 1 and 2 stratified by 
ancestry were meta-analyzed using weighting by standard errors. Although examination of 
the Cochran’s Q statistic suggested no heterogeneity across studies for the genetic factors in 
the meta-analyses (p>0.1), except rs16969968 in European Americans (p=0.02), to be 
consistent, all reported meta-analysis results are from random effects models. An ancestry 
specific study was included in the meta-analysis of the individual low frequency variants, if 
the minor allele of that variant occurred in at least 5 subjects in the population. This cut-off 
was used because random effects meta-analyses may be unstable or undefined for very rare 
events.
RESULTS
Variants identified in sequencing
Sequencing identified 26 coding variants in CHRNA5, including 2 frameshift deletions and 
24 nonsynonymous variants (details of these variants are in Figure 1 and Supplementary 
Table S1). The majority were predicted to be deleterious using a consensus protein 
prediction method.21 Interestingly, the well-studied rs16969968 variant was predicted to be 
neutral, supporting our approach of including all coding variants in the analyses.
Common CHRNA5 variant
The only common coding variant identified was the previously well-studied variant 
rs16969968 located in exon 5 of CHRNA5. In the primary sample, the rs16969968 minor 
allele was associated with increased risk for nicotine dependence in European (OR=1.3, 
p=0.003) and African Americans (OR=1.5, p=0.04) (Multivariate Model Set 1, Table 2). 
Replication results from 12 independent studies provide strong evidence that the A allele of 
rs16969968 increases risk for heaviness of smoking (Figure 2 and Supplementary Tables S2-
S3). Meta-analyses combining results from the primary and replication datasets demonstrate 
that rs16969968 has an OR of 1.3 in both European (p=3.7×10−11) and African Americans 
(p=0.01).
Aggregate low frequency CHRNA5 variants
Three low frequency, nonsynonymous CHRNA5 variants were identified. In the primary 
Multivariate Model Set 1, this aggregate low frequency term provided modest evidence for 
association in both populations (European: OR=1.8, p=0.06; African: OR=1.4, p=0.07) 
(Table 2). Results from the replication studies demonstrated a significant effect of the 
aggregated three low frequency variants on heaviness of smoking. The overall meta-analysis 
combining the primary and replication samples yielded an OR=1.3 in European Americans 
(p=0.005) and OR=1.4 in African Americans (p=0.0006) for the aggregate low frequency 
term.
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Individual low frequency CHRNA5 variants
In secondary analyses using Multivariate Model Set 2, we examined the independent 
contributions of the three low frequency variants to nicotine dependence risk controlling for 
the effect of other CHRNA5 coding variants. One of these low frequency variants was found 
primarily in European Americans, and the other two were almost exclusively in African 
Americans (Table 2).
The low frequency variant rs2229961 causes a valine to isoleucine change at position 134 in 
exon 4 in the extracellular domain of the receptor. The minor allele principally occurred in 
European Americans (MAF=0.02) and was rare in African Americans (MAF=0.002). In the 
primary sample, all 51 individuals with a copy of rs2229961 also possessed at least one copy 
of the rs16969968 minor (risk) allele, suggesting that these two coding variants are in 
linkage disequilibrium. Adjusting for the effect of rs16969968, the minor allele of 
rs2229961 was in the risk direction in European Americans (OR=1.7, p=0.1). Meta-analysis 
of these primary results and the independent replication samples yielded an OR=1.3 in 
European Americans (p=0.007) (Supplementary Table S4).
The minor allele of the second low frequency variant rs80087508 causes a lysine to arginine 
transition at position 167 in the extracellular domain of the receptor. This variant occurred 
exclusively in African Americans (MAF=0.01). This variant co-occurred with the common 
rs16969968 minor allele in 5 out of 38 individuals in the primary sample. In Multivariable 
Model Set 2 controlling for other coding variants, the minor allele of rs80087508 trended in 
the risk direction in African Americans (OR=2.1, p=0.06). Meta-analysis of these primary 
results and the 12 independent replication samples yielded an OR=1.6 in African Americans 
(p=0.02) (Supplementary Table S5).
The final low frequency variant, rs79109919, causes a leucine to glutamine change at amino 
acid position 363, which is located in the cytoplasmic domain of the receptor. The minor 
allele of rs79109919 was common in African Americans (MAF=0.06) and occurred in only 
one European American individual (MAF=0.0003) in the primary sample. Of the 158 
individuals who possessed at least one copy of the rs79109919 minor allele, 7 also possessed 
a copy of the rs16969968 risk allele and 1 possessed a copy of the low frequency 
rs80087508 variant, suggesting the independent transmission of these variants. In the 
primary sample, the minor allele of rs79109919 was in the risk direction in African 
Americans (OR=1.3, p=0.15). Meta-analysis of the primary and replication results yielded 
an OR=1.4 in African Americans (p=0.03) (Supplementary Table S5).
Aggregate rare CHRNA5 variants
Sequencing identified 22 rare coding variants (MAF<0.5%) (20 nonsynonymous variants 
and 2 frameshift deletions). These variants occurred throughout the protein sequence (Figure 
1). Each variant occurred in 1-4 individuals in the primary sample (Supplementary Figure 
S1). Furthermore, 9 of the 22 rare variants were seen in a single individual and were 
previously unreported in large reference datasets20 (Exome Variant Server) (Supplementary 
Table S1).
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Because these variants occurred in only a limited number of individuals, we used a 
collapsing burden test to assess their cumulative effect after adjusting for the effect of 
rs16969968 and low frequency variants. Overall, 37 individuals possessed at least 1 rare 
variant (details of these individuals in Supplemental Table S6). In the primary sample, the 
aggregate rare variant term was associated with a risk effect in the European Americans 
(OR=12.9, p=0.01) as 12/13 (92%) individuals with at least one rare variant were nicotine 
dependent cases (Table 2, Table S6). In African Americans, the rare variant term was in the 
same risk direction but not significant (OR=1.5, p=0.37) as 17/24 (71%) of the individuals 
with at least one rare variant were nicotine dependent cases.
Phenotypic variation accounted for by testing genetic factors
Nagelkerke’s adjusted R2 was used to assess the proportion of nicotine dependence variation 
explained by individual SNPs and multivariable models in the primary sample (Table 3). The 
overall phenotypic variance explained by the genetic variants in this one gene was 2.4% in 
European Americans and 1.0% in African Americans.
DISCUSSION
This study demonstrates that common, low frequency, and rare CHRNA5 coding variants 
independently increase risk for nicotine dependence in both European and African 
Americans. An important strength of our study was the large sample of African Americans, 
a population often under-represented in genetic studies. Differences in the genetic 
architecture of European and African ancestry groups indicate that distinct genetic factors 
differentially contribute to nicotine dependence in these populations. These differences are 
highlighted by the fact that the well-established coding variant in CHRNA5, rs16969968, is 
more common in European (MAF=0.35) than African Americans (MAF=0.06). Importantly, 
we identify and replicate new associations with nicotine dependence for three low frequency, 
nonsynonymous variants, two of which almost exclusively occur in African Americans 
(rs80087508 and rs79109919).
Our targeted sequencing of CHRNA5 in approximately 3000 nicotine dependent cases and 
non-dependent controls builds upon previous exome chip and sequencing studies of other 
smoking-related measures.22,28-30 Sequencing a large, diverse, unrelated sample (n=2820) 
enabled us to identify many more coding variants of high quality (n=26), including 9 novel 
variants, and demonstrate association with nicotine dependence.
Using exome chip data from 12 studies containing over 10 000 heavy and 10 000 light 
smokers, we replicated our novel associations between low frequency CHRNA5 coding 
variants and smoking behaviors observed through our targeted sequencing. Our replication 
study design of examining phenotypic extremes of smoking quantity (heavy vs light 
smokers) reduces classification errors and reproduced the robust associations between 
common and low frequency nonsynonymous CHRNA5 variants seen in our discovery 
sample with nicotine dependence.
Because multiple independent CHRNA5 risk variants were identified, a critical question is 
what proportion of phenotypic variance is explained by coding variation in this one gene. 
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Genetic studies of complex traits have identified reproducible associations, but these 
findings often explain a modest proportion of phenotypic variance.31 For nicotine 
dependence, rs16969968, arguably the single strongest genetic risk factor in European 
ancestry populations, accounts for 1.0% of variance in European Americans in our study and 
others.32_ENREF_10 The addition of low frequency and rare coding variants increased the 
estimated phenotypic variance explained by this gene in European Americans to 2.4%. In 
African Americans, though rs16969968 is less common and therefore explains a smaller 
proportion of estimated phenotypic variance (R2=0.4%), adding low frequency and rare 
coding variants increased this estimate (R2=1.0%). Since self-reported smoking behaviors 
are crude measures of exposure to nicotine, the variance explained by these polymorphisms 
for biomarkers of smoking such as carbon monoxide and cotinine will likely be greater.33,34 
For example rs16969968 explained four to five times more of the variance in carbon 
monoxide and cotinine levels compared to self-reported cigarette consumption.32,33 
Similarly, we hypothesize that these low frequency and rare CHRNA5 coding variants will 
explain much more of the variance of these biomarkers.
The findings reported here have limitations. Because the nonsynonymous rs16969968 
variant in CHRNA5 is associated with changes in nicotinic receptor function,4,16 we 
hypothesized that other coding variants will have a similar effect, but functional studies will 
need to confirm this. Noncoding variants have been previously associated with changes in 
CHRNA5 mRNA expression levels in the brain35-37 as well as nicotine dependence and lung 
cancer. Including these non-coding variants in the analyses of our primary sample did not 
appreciably alter the associations with the coding variants. Because replication analyses 
were based on exome chip data, the contribution of these non-coding variants could not be 
further tested. In addition, the majority of rare variants are also not available on the exome 
chip, and therefore typing of these rare variants is required for replication. Another 
limitation is that our analysis is restricted to a single gene. Other nicotinic receptors 
contribute to nicotine dependence.30,38
From a public health perspective, these newly identified low frequency and rare CHRNA5 
coding variants will likely have important prognostic and therapeutic implications. The 
common CHRNA5 coding variant (rs16969968) is a strong genetic risk factor for lung 
cancer and chronic obstructive pulmonary disease2,7,8,10 and also influences response to 
smoking cessation therapies.6 Though these low frequency and rare variants will have a 
smaller impact on a population based level, from an individual viewpoint, the presence of 
these risk variants has a strong effect on the development of nicotine dependence. An 
important next step is to test whether these low frequency and rare CHRNA5 coding variants 
similarly increase the risk of smoking-related diseases such as lung cancer.
In summary, multiple rare, low frequency and common variants in the CHRNA5 gene 
contribute to the development of nicotine dependence. This study is another example of how 
sequencing a gene associated with a disease can identify additional variants which then 
explain more of the missing genetic variance.
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Figure 1. 
Protein Schematic of CHRNA5 nonsynonymous and frameshift variants. Bold underline 
indicates the only common variant (MAF>5%); Bold indicates low frequency variants 
(5%>MAF≥0.5%); Other variants are rare (MAF<0.5%).
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Figure 2. 
Forest plots showing the primary sample, replication samples, and random effects meta-
analyses from Multivariable Model Set 1. (a) rs16969968 in European Americans; (b) 
aggregate low frequency variant term in European Americans; (c) rs16969968 in African 
Americans; (d) aggregate low frequency variant term in African Americans.
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Table 1
Characteristics of primary sample
European American
(n=1432)
African American
(n=1388)
cases controls cases controls
Sample, n 728 704 854 534
Age, mean (range) 37 (25-45) 36 (25-45) 36 (25-45) 36 (25-45)
Sex
  Female 386 (53%) 482 (68%) 514 (60%) 321 (60%)
  Male 342 (47%) 222 (32%) 340 (40%) 213 (40%)
FTND1 score, mean (range) 6.49 (4-10) 0.02 (0-1) 6.21 (4-10) 0.33 (0-1)
CPD2 category, mean (range) 1.94 (0-3) 0.01 (0-1) 1.11 (0-3) 0.03 (0-1)
1FTND is the Fagerström Test for Nicotine Dependence
2CPD is categorical cigarettes per day (1 is ≤10, 2 is 11-20, 3 is 21-30, 4 is >30);
Mol Psychiatry. Author manuscript; available in PMC 2016 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Olfson et al. Page 17
Table 2
The effect of common, low frequency, and rare CHRNA5 coding variants on nicotine dependence in primary 
sample
Variant Class Variant
European Americans (n=1432) African Americans (n=1388)
MAF1 OR (95% CI) p-value MAF OR (95% CI)
p-
value
Multivariable Model Set 1
Common rs16969968 0.355 1.27(1.08-1.49) 0.003 0.058
1.46
(1.02-2.07) 0.04
Low Frequency
Aggregate
term2
0.016 1.81(0.97-3.42) 0.06 0.071
1.35
(0.98-1.87) 0.07
Rare Aggregateterm 0.005 12.90 (1.66-100.54) 0.01 0.009
1.47
(0.60-3.59) 0.40
Multivariable Model Set 2
Common rs16969968 0.355 1.28(1.09-1.50) 0.003 0.058
1.42
(1.00-2.03) 0.05
Low Frequency
rs2229961 0.016 1.71(0.91-3.23) 0.10 0.002
2.57
(0.28-23.91) 0.41
rs80087508 03 . . 0.014
2.00
(0.94-4.27) 0.07
rs79109919 0.00034 . . 0.057 1.22 (0.86-1.75) 0.26
Rare Aggregateterm 0.005
12.91
(1.66-100.66) 0.01 0.009
1.51
(0.62-3.68) 0.37
This table shows the genetic effect of CHRNA5 coding variants analyzed jointly in multivariate model sets 1 and 2.
Multivariable Model Set 1 includes rs16969968, the aggregate low frequency variant term, and the aggregate rare variant term:
Multivariable Model Set 2 includes rs16969968, rs2229961, rs800087508, rs79109919, and the aggregate rare variant term;
All models adjusted for sex, age, and first ancestry-specific PC as covariates;
1MAF stands for minor allele frequency;
2for aggregate terms, the MAF was estimated by the dividing the number of people with at least one low frequency/rare variant by 2 times the total 
number of people;
3rs80087508 is non-polymorphic in European Americans;
4Because the minor allele of rs79109919 occurred less than 5 times in European Americans, the OR and p-value are not presented.
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Table 3
Variation in nicotine dependence risk explained by selected variants in primary sample
Variant Class Variant
European Americans (n=1432) African Americans (n=1388)
MAF R2 p-value MAF R2 p-value
Common rs16969968 0.355 1.0% 0.001 0.058 0.4% 0.04
Low Frequency
rs2229961 0.016 0.4% 0.03 0.002 0.1% 0.24
rs80087508 0 . . 0.014 0.3% 0.07
rs79109919 0.0003 0.2% 0.15 0.057 0.1% 0.34
Rare aggregate term 0.005 1.0% 0.0009 0.009 0.1% 0.37
All CHRNA5 genetic terms 2.4% 5.5 ×10−5 1.0% 0.07
This table shows the variance explained by each individual variant and aggregate term by itself, as well as the variance explained by all CHRNA5 
genetic variants examined jointly in the final model. This final model includes rs16969968, rs2229961, rs800087508, rs79109919, and the 
aggregate rare variant term;
R2 is the Nagelkerke’s adjusted R2 difference from logistic regression, comparing the base model with intercept, sex, age, and ancestry specific 
PCs to models with genetic variants;
p-values calculated by taking the difference between the -2logliklihoods in the base model and those with variants as a chi-square statistic.
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